A GLOBAL

LEADER IN DRUG

DISCOVERY AND

DEVELOPMENT

Science

The pharmacology experimental platform allows KBP to identify and progress those
products with significant differentiation.

Platform

The platform is well integrated with KBP’s compound library and the bacteria collection.

Disease Areas

KBP is dedicated to research and development of novel solutions of hypertension, cardiorenal, and infectious diseases around the world.

Pipeline

Benefiting from our proprietary R&D platform, we have established a strong pipeline of clinical and preclinical programs.

Recent News

View recent and past KBP stories,
including press releases and media coverages.

KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease Patients

KBP Biosciences Doses Final Patient in BLOCK CKD Phase 2b Study of KBP-5074

KBP Biosciences Announces Peer-Reviewed Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension

KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe Chronic Kidney Disease (CKD) patients with and without hemodialysis

KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074

KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter Baumannii

KBP Biosciences Appoints Nick Hart as Chief Financial Officer

KBP Biosciences to Present at Biotech Showcase 2020

KBP BIOSCIENCES SIGNS MEMORANDUM OF UNDERSTANDING WITH BULLFROG AI

Our Company

KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs.

Our integrated discovery and development platform enables us to efficiently bring new drugs from bench to clinics around the world.

Corporate Presentation(EN)